Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HT61 nasal gel proof-of-concept study in Staphylococcus aureus nasal carriers
2008-000474-20Phase 2Completed
- Sponsor
- Helperby Therapeutics
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind trial of HT61 in Staphylococcus aureus nasal carriage (4 arms), sponsored by Helperby Therapeutics. Primary endpoint: Plasma HT61 absorption levels. Started Jan 2009; status: completed.
02
Drugs
HT61
03
Conditions
Staphylococcus aureus nasal carriage
Beyond the preview
Go deeper on 2008-000474-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000474-20.